GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Zydus Lifesciences Ltd (BOM:532321) » Definitions » Total Long-Term Liabilities

Zydus Lifesciences (BOM:532321) Total Long-Term Liabilities : ₹18,017 Mil (As of Mar. 2025)


View and export this data going back to 2000. Start your Free Trial

What is Zydus Lifesciences Total Long-Term Liabilities?

Total Long-Term Liabilities includes Long-Term Debt & Capital Lease Obligation, PensionAndRetirementBenefit, NonCurrent Deferred Liabilities and Other Long-Term Liabilities. Zydus Lifesciences's Total Long-Term Liabilities for the quarter that ended in Mar. 2025 was ₹18,017 Mil.

Zydus Lifesciences Total Long-Term Liabilities Historical Data

The historical data trend for Zydus Lifesciences's Total Long-Term Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zydus Lifesciences Total Long-Term Liabilities Chart

Zydus Lifesciences Annual Data
Trend Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25
Total Long-Term Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 10,938.00 9,022.00 5,374.00 18,373.00 18,017.00

Zydus Lifesciences Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Total Long-Term Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 18,373.00 - 19,399.00 - 18,017.00

Zydus Lifesciences Total Long-Term Liabilities Calculation

Total Long-Term Liabilities represents the obiligation that incurred as part of normal operations that is expected to be repaid beyond the following twelve months or one business cycle, excluding minority interest. It includes Long-Term Debt & Capital Lease Obligation, PensionAndRetirementBenefit, NonCurrent Deferred Liabilities and Other Long-Term Liabilities.

Zydus Lifesciences Total Long-Term Liabilities Related Terms

Thank you for viewing the detailed overview of Zydus Lifesciences's Total Long-Term Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Zydus Lifesciences Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Zydus Lifesciences Ltd (BOM:532321) » Definitions » Total Long-Term Liabilities
Comparable Companies
BOM:500257 BOM:543904 BOM:500124 NSE:TORNTPHARM NSE:AUROPHARMA BOM:500488 NSE:ALKEM BOM:500087 BOM:543064 BOM:532296 ZTS XTER:MRK LSE:HLN NSE:SUNPHARMA TSE:4502 XSWX:GALD XSWX:SDZ NSE:DIVISLAB HKSE:03692 XTAE:TEVA
Traded in Other Exchanges
ZYDUSLIFE:India
Address
Scheme No. 63, Sarkhej-Gandhinagar Highway, Zydus Corporate Park, Survey No. 536, Near Vaishnodevi Circle, Khoraj (Gandhinagar), Ahmedabad, GJ, IND, 382481
Website
https://www.zyduslife.com
Zydus Lifesciences Ltd is a specialty and generic drug manufacturing company. It is engaged in the research, development, production, marketing, and distribution of pharmaceutical products. The product portfolio of the company includes Active Pharmaceutical Ingredients (API), human formulations, animal health and veterinary, and consumer health and wellness products. Its products are marketed under brands like Amlodac, Inditel, Pivasta, and others. The company's operating segments are; Pharmaceuticals which derives key revenue, and Consumer products. Geographically, it generates maximum revenue from the United States followed by India, and other countries.

Zydus Lifesciences Headlines

No Headlines